Pharmacist-based deprescribing successfully reduced older adults' exposure to anticholinergic drugs

"Our new study is important, necessary preliminary work, enabling us to test whether deprescribing these drugs improves clinical outcomes," said Regenstrief Institute and Purdue College of Pharmacy faculty member Noll Campbell, PharmD, M.S., who led the new study to develop pharmacist-centric delivery models to successfully switch patients to safer drugs. "Tackling deprescribing has not been easy. That pharmacist-centric deprescribing models work so well does not surprise me because pharmacists are well suited for the task. They are knowledgeable about medications, often have a close relationship with the patients and are well trained to communicate with providers."

The researchers developed two pharmacist-focused deprescribing models. One, a face-to-face model involved pharmacists meeting with and monitoring older adult patients being seen in an aging brain care clinic. The second model, which involved pharmacist outreach via telephone to a generally older adult patient population encouraging safer medications, was less effective in diminishing exposure to anticholinergics but more effective than other methodologies, including clinician alerts in electronic health records (EHRs). Collectively, these models decreased prescription of anticholinergics by 73 percent and reduced cumulative use of these drugs by as much as 70 percent.

"Deprescribing anticholinergics in primary care older adults: Experience from two models and impact on a continuous measure of exposure" is published in the peer-reviewed Journal of the American College of Clinical Pharmacy (JACCP). Authors, in addition to Dr. Campbell are Christopher Callahan, M.D., and Malaz Boustani, M.D., MPH, Regenstrief Institute, IU School of Medicine and Eskenazi Health; Christopher Pitts, PharmD, and Parveen Chand, MHA, IU Health; Claire Corvari, PharmD, Franciscan Health;Ellen Kaehr, M.D.,IU School of Medicine; Khalid Alamer, PharmD, PhD candidate, Purdue University College of Pharmacy; Kristine Nanagas, M.D., IU Health and IU School of Medicine.

The study was supported by the National Institutes of Health's National Institute on Aging [K23AG044440 and R01AG061452] and the Agency for Healthcare Research and Quality [P30HS2 4384].

Using the human-intensive deprescribing methodologies described in the JACCP paper, Regenstrief researchers are currently conducting R2D2 -- an acronym for "Reducing Risk of Dementia through Deprescribing" to determine whether the adverse cognitive effects of anticholinergic medications are reversible. In this study, which is currently recruiting patients, clinical pharmacists are working with physicians and their patients who are using anticholinergics to identify and switch to safer alternative medications. The trial also monitors the effect of deprescribing these medications on depression, anxiety, pain, insomnia, and quality of life. Dr. Campbell leads this National Institutes of Health's National Institute on Aging funded study.